Baseline characteristics of the different patient groups
| Non-switchers | Switchers | ||
|---|---|---|---|
| 1st TNFi | 2nd TNFi | ||
| n=344 | n=95 | n=95 | |
| All patients | |||
| Age | 46.8 (11.7) | 46.1 (11.6) | 47.7 (11.5) |
| Male sex (%) | 55.2 | 48.4 | 48.4 |
| Type of TNFi (%) | |||
| Etanercept | 49.4 | 52.6 | 32.6 |
| Infliximab | 10.5 | 13.7 | 16.8 |
| Adalimumab | 29.1 | 29.5 | 36.8 |
| Golimumab | 10.5 | 4.2 | 11.6 |
| Certolizumab | 0.6 | 0 | 2.1 |
| Co-medication with synthetic DMARD (%) | 63.7 | 55.8 | 54.7 |
| Disease duration (years)* | 6.0 (1.5–12.4) | 4.7 (1.3–13.8) | 6.5 (2.7–14.2) |
| Current smoker (%) | 29.9 | 30.9 | 32.6 |
| Previously used synthetic DMARDs | 1.5 (1.1) | 1.7 (1.1) | 1.7 (1.1) |
| Follow-up time (days)* | 614 (190–1210) | 255 (111–753) | 235 (88–611) |
| Physician global assessment (0–100) | 36.5 (17.5) | 39.5 (18.4) | 34.7 (18.6) |
| Patient global assessment (0–100) | 53.2 (22.9) | 57.4 (21.2) | 55.3 (22.7) |
| MHAQ score* | 0.63 (0.38–1.00) | 0.75 (0.50–1.00) | 0.75 (0.38–1.00) |
| SF-6D | 0.59 (0.12) | 0.58 (0.11) | 0.59 (0.13) |
| % With swollen joints at baseline | 76.1 | 83.9 | 74.2 |
| CRP (mg/l)* | 9 (5–20) | 8 (4–27) | 5 (2–19)† |
| Patients with swollen joints at baseline‡ | n=252 | n=84 | n=84 |
| Swollen joints (0–32)* | 4 (2–7) | 3 (2–7) | 3 (1–5)† |
| DAS28 | 4.50 (1.21) | 4.57 (1.25) | 4.32 (1.43) |
All values are mean (SD) unless stated otherwise.
*Median (IQR).
†Statistically significant difference from non-switchers.
‡For switchers, patients with swollen joints at baseline when receiving first and/or second TNFi are included. MHAQ, Modified health assessment questionnaire (0–3), SF-6D=Short form 6-dimensions (0–1).